Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis ; volume:40 ; number:2 ; day:2 ; month:11 ; year:2019 ; pages:129-137 ; date:2.2020
Clinical drug investigation ; 40, Heft 2 (2.11.2019), 129-137, 2.2020
- Creator
-
Liu, Qiao
Luo, Xia
Peng, Liubao
Yi, Lidan
Wan, Xiaomin
Zeng, Xiaohui
Tan, Chongqing
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-019-00869-3
- URN
-
urn:nbn:de:101:1-2020050119485983561460
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liu, Qiao
- Luo, Xia
- Peng, Liubao
- Yi, Lidan
- Wan, Xiaomin
- Zeng, Xiaohui
- Tan, Chongqing
- SpringerLink (Online service)
Other Objects (12)
The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data
Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data
Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data
Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population